CBER's Regulatory Activity in 2018: A Reading List
Executive SummaryThe US FDA's biologics center invested heavily in preparation for coming waves of advanced therapies.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
The latest drug development news and highlights from our US FDA Performance Tracker.